72 related articles for article (PubMed ID: 36206664)
1. Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity.
Yang S; Shim MK; Song S; Cho H; Choi J; Jeon SI; Kim WJ; Um W; Park JH; Yoon HY; Kim K
Biomaterials; 2022 Nov; 290():121841. PubMed ID: 36206664
[TBL] [Abstract][Full Text] [Related]
2. Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy.
Lee Y; Song S; Yang S; Kim J; Moon Y; Shim N; Yoon HY; Kim S; Shim MK; Kim K
Acta Pharm Sin B; 2024 Mar; 14(3):1428-1440. PubMed ID: 38487005
[TBL] [Abstract][Full Text] [Related]
3. All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy.
Song S; Shim MK; Yang S; Lee J; Yun WS; Cho H; Moon Y; Min JY; Han EH; Yoon HY; Kim K
Bioact Mater; 2023 Oct; 28():358-375. PubMed ID: 37334068
[TBL] [Abstract][Full Text] [Related]
4. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
Kim J; Shim MK; Moon Y; Kim J; Cho H; Yun WS; Shim N; Seong JK; Lee Y; Lim DK; Kim K
J Nanobiotechnology; 2024 Mar; 22(1):109. PubMed ID: 38481326
[TBL] [Abstract][Full Text] [Related]
5. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer.
Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
[TBL] [Abstract][Full Text] [Related]
6. Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade.
Zhang B; Li N; Gao J; Zhao Y; Jiang J; Xie S; Zhang C; Zhang Q; Liu L; Wang Z; Ji D; Wu L; Ren R
J Exp Clin Cancer Res; 2024 Feb; 43(1):51. PubMed ID: 38373953
[TBL] [Abstract][Full Text] [Related]
7. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
Liu D; Li K; Gong L; Fu L; Yang D
Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Immunosuppressive Tumors by Polymer-Assisted Inductions of Immunogenic Cell Death and Multivalent PD-L1 Crosslinking.
Li L; Li Y; Yang CH; Radford DC; Wang J; Janát-Amsbury M; Kopeček J; Yang J
Adv Funct Mater; 2020 Mar; 30(12):. PubMed ID: 33071706
[TBL] [Abstract][Full Text] [Related]
9. Designing Peptide-Based Nanoinhibitors of Programmed Cell Death Ligand 1 (PD-L1) for Enhanced Chemo-immunotherapy.
Xie F; Tang S; Zhang Y; Zhao Y; Lin Y; Yao Y; Wang M; Gu Z; Wan J
ACS Nano; 2024 Jan; 18(2):1690-1701. PubMed ID: 38165832
[TBL] [Abstract][Full Text] [Related]
10. Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3.
Wang Q; Wang J; Yu D; Zhang Q; Hu H; Xu M; Zhang H; Tian S; Zheng G; Lu D; Hu J; Guo M; Cai M; Geng X; Zhang Y; Xia J; Zhang X; Li A; Liu S; Zhang W
Cell Rep Med; 2024 Feb; 5(2):101357. PubMed ID: 38237597
[TBL] [Abstract][Full Text] [Related]
11.
Zhu Q; Wang H; Chai S; Xu L; Lin B; Yi W; Wu L
Proc Natl Acad Sci U S A; 2023 Mar; 120(13):e2216796120. PubMed ID: 36943877
[TBL] [Abstract][Full Text] [Related]
12. A Novel Tri-Functional Liposome Re-Educates "Cold Tumor" and Abrogates Tumor Growth by Synergizing Autophagy Inhibition and PD-L1 Blockade.
Zhou F; Li X; Xue X; Li S; Fan G; Cai Y; Chang Z; Qu J; Liu R
Adv Healthc Mater; 2023 Apr; 12(11):e2202757. PubMed ID: 36652763
[TBL] [Abstract][Full Text] [Related]
13. Construction of the systemic anticancer immune environment in tumour-bearing humanized mouse by using liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated progesterone.
Kametani Y; Ito R; Ohshima S; Manabe Y; Ohno Y; Shimizu T; Yamada S; Katano N; Kirigaya D; Ito K; Matsumoto T; Tsuda B; Kashiwagi H; Goto Y; Yasuda A; Maeki M; Tokeshi M; Seki T; Fukase K; Mikami M; Ando K; Ishimoto H; Shiina T
Front Immunol; 2023; 14():1173728. PubMed ID: 37492571
[TBL] [Abstract][Full Text] [Related]
14. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.
Xu X; Xie T; Zhou M; Sun Y; Wang F; Tian Y; Chen Z; Xie Y; Wu R; Cen X; Zhou J; Hou T; Zhang L; Huang C; Zhao Q; Wang D; Xia H
Nat Commun; 2024 May; 15(1):4237. PubMed ID: 38762492
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Tumor Immunotherapy by Multivalent Anti-PD-L1 Nanobody Assembled via Ferritin Nanocage.
Liu M; Jin D; Yu W; Yu J; Cao K; Cheng J; Zheng X; Wang A; Liu Y
Adv Sci (Weinh); 2024 May; 11(20):e2308248. PubMed ID: 38491904
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting autophagy to boost antitumor immunity with tetramethylpyrazine-loaded and PD-L1-targeting liposomal nanoparticles.
Zhou F; Li X; Jia K; Li F; Xue X; Liu J; Qu J; Liu R
Eur J Pharm Sci; 2023 Nov; 190():106581. PubMed ID: 37696460
[TBL] [Abstract][Full Text] [Related]
17. GE11-modified carboxymethyl chitosan micelles to deliver DOX·PD-L1 siRNA complex for combination of ICD and immune escape inhibition against tumor.
Song P; Wang B; Pan Q; Jiang T; Chen X; Zhang M; Tao J; Zhao X
Carbohydr Polym; 2023 Jul; 312():120837. PubMed ID: 37059562
[TBL] [Abstract][Full Text] [Related]
18. Manipulation of PD-L1 Endosomal Trafficking Promotes Anticancer Immunity.
Ye Z; Xiong Y; Peng W; Wei W; Huang L; Yue J; Zhang C; Lin G; Huang F; Zhang L; Zheng S; Yue J
Adv Sci (Weinh); 2023 Feb; 10(6):e2206411. PubMed ID: 36567273
[TBL] [Abstract][Full Text] [Related]
19. Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes.
Gabizon A; Shmeeda H; Draper B; Parente-Pereira A; Maher J; Carrascal-Miniño A; de Rosales RTM; La-Beck NM
Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004584
[TBL] [Abstract][Full Text] [Related]
20. A Nanobody-Bioorthogonal Catalyst Conjugate Triggers Spatially Confined Prodrug Activation for Combinational Chemo-immunotherapy.
Zhao Z; Wang X; Wang J; Li Y; Lin W; Lu K; Chen J; Xia W; Mao ZW
J Med Chem; 2023 Sep; 66(17):11951-11964. PubMed ID: 37590921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
